Harvard Bioscience
HBIO
80 hedge funds and large institutions have $109M invested in Harvard Bioscience in 2014 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 7 closing their positions.
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
47% more capital invested
Capital invested by funds: $74.1M → $109M (+$34.6M)
11% more funds holding
Funds holding: 72 → 80 (+8)
29% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$1.66M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$1.44M |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
+$842K |
| 4 |
GPC
Glacier Peak Capital
Bellevue,
Washington
|
+$710K |
| 5 |
TA
Teton Advisors
Rye,
New York
|
+$649K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Centaur Capital Partners
Southlake,
Texas
|
-$1.06M |
| 2 |
Morgan Stanley
New York
|
-$910K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$382K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$196K |
| 5 |
Renaissance Technologies
New York
|
-$154K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Citigroup
New York
| $1K | -$143 | -3 | -11% |
|
|
TDC
77
Thompson Davis & Co
Richmond,
Virginia
| $1K | +$1.19K | +25 | New |
|
|
PPA
78
Parametric Portfolio Associates
Seattle,
Washington
| – | -$196K | -4,799 | Closed |
|
|
LP
79
LMR Partners
London,
United Kingdom
| – | -$144K | -3,543 | Closed |
|
80
Schroder Investment Management Group
London,
United Kingdom
| – | -$3.91K | -96 | Closed |
|
81
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$2K | -40 | Closed |
|
|
TRCT
82
Tower Research Capital (TRC)
New York
| – | -$1K | -29 | Closed |
|
83
Creative Planning
Overland Park,
Kansas
| – | +$191 | +4 | New |
|
84
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$667 | +14 | New |
|
85
SEI Investments
Oaks,
Pennsylvania
| – | +$905 | +19 | New |
|
HBIO Hedge Fund Activity: Q4 2014 in Review
80 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q4 2014, worth a combined $109M — up 47% from $74.1M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new HBIO positions and 7 closed out — a net gain of 9 holders — while 17 added to existing stakes and 24 trimmed.
The largest buyer was First Light Asset Management, adding an estimated $1.66M. The largest seller was Centaur Capital Partners, cutting an estimated $1.06M.
- 80 institutional investors held Harvard Bioscience (HBIO) as of Q4 2014, up from 72 in Q3 2014.
- Funds reported $109M of Harvard Bioscience stock for Q4 2014, up 47% quarter-over-quarter.
- 16 funds opened new Harvard Bioscience positions in Q4 2014 and 7 closed out, a net change of +9 holders.
- The largest Harvard Bioscience buyer in Q4 2014 was First Light Asset Management, an estimated $1.66M added.
- The largest Harvard Bioscience seller in Q4 2014 was Centaur Capital Partners, an estimated $1.06M sold.
Based on aggregated 13F filings for Q4 2014.